Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Advaxis, Inc. (ADXS)

2.4   0.04 (1.69%) 01-27 15:49
Open: 2.36 Pre. Close: 2.36
High: 2.4 Low: 2.2
Volume: 4,499 Market Cap: 4(M)

Technical analysis

as of: 2023-01-27 4:42:18 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 4.38     One year: 5.11
Support: Support1: 2.05    Support2: 1
Resistance: Resistance1: 3.75    Resistance2: 4.38
Pivot: 2.08
Moving Average: MA(5): 2.39     MA(20): 1.87
MA(100): 1.94     MA(250): 4.35
MACD: MACD(12,26): 0.2     Signal(9): 0.2
Stochastic oscillator: %K(14,3): 48.6     %D(3): 48.8
RSI: RSI(14): 61.4
52-week: High: 11.52  Low: 0.05
Average Vol(K): 3-Month: 6 (K)  10-Days: 13 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ ADXS ] has closed below upper band by 35.8%. Bollinger Bands are 162.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.4 - 2.42 2.42 - 2.43
Low: 2.17 - 2.18 2.18 - 2.2
Close: 2.37 - 2.4 2.4 - 2.42

Company Description

Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.

Headline News

Thu, 19 Jan 2023
Other news to note for Jan. 19, 2023 - BioWorld Online

Thu, 19 Jan 2023
Advaxis and Ayala Pharmaceuticals Complete Merger - GlobeNewswire

Wed, 18 Jan 2023
Ayala sees last day of trading as merger with Advaxis takes place ... - Seeking Alpha

Thu, 12 Jan 2023
Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer - Yahoo Finance

Thu, 20 Oct 2022
Advaxis enters merger deal with biotech firm Ayala - Pharmaceutical Technology

Wed, 19 Oct 2022
Advaxis and Ayala Pharmaceuticals Enter into Merger Agreement - GlobeNewswire

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  PNK
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 2 (M)
% Held by Insiders 1.82e+006 (%)
% Held by Institutions 0 (%)
Shares Short 45 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.531e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -6
Return on Assets (ttm) 264.3
Return on Equity (ttm) -24.2
Qtrly Rev. Growth 250000
Gross Profit (p.s.) 0
Sales Per Share -19.53
EBITDA (p.s.) 1.50698e+006
Qtrly Earnings Growth -0.1
Operating Cash Flow 0 (M)
Levered Free Cash Flow -16 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.13
Price to Cash Flow 0.33

Stock Dividends

Dividend 0
Forward Dividend 39890
Dividend Yield 0%
Dividend Pay Date 2019-03-28
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.